Brain-derived neurotrophic factor and electroconvulsive therapy in a schizophrenic patient with treatment-resistant paranoid-hallucinatory symptoms

Journal of ECT

Volumn 27, Issue 1, 2011, Pages e44-e46

  Martinotti, Giovanni ^a,b   Ricci, Valerio ^b,c   Di Nicola, Marco ^a,b   Caltagirone, Carlo ^c   Bria, Pietro ^a   Angelucci, Francesco ^c  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^b Neuropsychiatric Clinic Villa Maria Pia   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

BDNF; ECT; Schizophrenia

Indexed keywords

BIPERIDEN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; CLONAZEPAM; HALOPERIDOL; LORAZEPAM; OLANZAPINE; PALIPERIDONE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; SUXAMETHONIUM; THIOPENTAL; VENLAFAXINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; ELECTROCONVULSIVE THERAPY; HALLUCINATION; HUMAN; MALE; PARANOIA; PATHOGENESIS; SCHIZOPHRENIA; SYMPTOM;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; ELECTROCONVULSIVE THERAPY; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 79952193159     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e318205e1c0     Document Type: Article

References (31)

1. Cristancho MA, Alici Y, Augoustides JG, et al. Uncommon but serious complications associated with electroconvulsive therapy: recognition and management for the clinician. Curr Psychiatry Rep. 2008;10: 474-480.
2. Gao J, Wang WY, Mao YW, et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature. 2010;466: 1105-1109.
3. Angelucci F, Brene S, Mathé AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry. 2010;10: 345-352.
4. Tan YL, Zhou DF, Zhang XY. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res. 2005;74: 263-270.
5. Weickert CS, Ligons DL, Romanczyk T, et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry. 2005;10: 637-650.
6. Duman RS, Vaidya VA. Molecular and cellular actions of chronic electroconvulsive seizures. J ECT. 1998;14: 181-193.
7. Chen AC, Eisch AJ, Sakai N, et al. Regulation of GFRalpha-1 and GFRalpha-2 mRNAs in rat brain by electroconvulsive seizure. Synapse. 2001;39: 42-50.
8. Altar CA, Whitehead RE, Chen R, et al. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry. 2003;54: 703-709.
9. Katoh-Semba R, Takeuchi IK, Inaguma Y, et al. Brain-derived neurotrophic factor, nerve growth and neurotrophin-3 selected regions of the rat brain following kainic acid-induced seizure activity. Neurosci Res. 1999;35: 19-29.
10. Rosa DV, Souza RP, Souza BR, et al. DARPP-32 expression in rat brain after electroconvulsive stimulation. Brain Res. 2007;1179: 35-41.
11. Rosa DV, Souza RP, Souza BR, et al. NCS-1 expression in rat brain after electroconvulsive stimulation. Neurochem Res. 2007;32: 81-85.
12. Krystal AD, Weiner RD. EEG correlates of the response to ECT: a possible antidepressant role of brain-derived neurotrophic factor. J ECT. 1999;15: 27-38.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC.: American Psychiatric Press, Inc; 2000.
14. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic, a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45: 789-796.
15. Abrams R, Swartz CM. ECT Instruction Manual. 3rd ed. Lake Bluff, IL: Somatics Inc; 1989.
16. Royal College of Psychiatrists. The ECT handbook. In: Freeman CP, ed. The Second Report of the Royal College of Psychiatrist’s Special Committee on ECT. London: Royal College of Psychiatrists; 1995.
17. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psycol Rep. 1962;10: 799.
18. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardization. Br J Psychiatry. 1989;155: 59-65.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23: 56-62.
20. Bocchio-Chiavetto L, Zanardini R, Bortolomasi M, et al. Electroconvulsive therapy (ECT) increases serum brain derived neurotrophic factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol. 2006;16: 620-624.
21. Marano CM, Phatak P, Vemulapalli UR, et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry. 2007;68: 512-517.
22. Okamoto T, Yoshimura R, Ikenouchi-Sugita A, et al. Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32: 1185-1190.
23. Taylor SM. Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive therapy. J ECT. 2008;24: 160-165.
24. Piccinni A, Del Debbio A, Medda P, et al. Plasma brain-derived neurotrophic factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol. 2009;19: 349-355.
25. Hu Y, Yu X, Yang F, et al. The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J ECT. 2010;26: 121-125.
26. Gronli O, Stensland GO, Wynn R, et al. Neurotrophic factors in serum following ECT: a pilot study. World J Biol Psychiatry. 2009;10: 295-301.
27. Fernandes B, Gama CS, Massuda R, et al. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients. Neurosci Lett. 2009;453: 95-98.
28. Huuhka K, Anttila S, Huuhka M, et al. Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with response to electroconvulsive therapy in major depressive disorder. Eur Arch Psychiatry Clin Neurosci. 2007;257: 31-35.
29. Smith SE, Acton L, Sharp T. Enhancement of dopamine-mediated behaviour by the NMDA antagonists MK-801 and CPP: similarities with repeated electroconvulsive shock. Psychopharmacology. 1997;133: 85-94.
30. Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991;350: 230-232.
31. Thoenen H. Neurotrophins and neuronal plasticity. Science. 1995;270: 593-598.